- Home
- MAZE vs RCS Comparison
MAZE vs RCS Comparison
Compare MAZE & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- RCS
- Stock Information
- Founded
- MAZE 2018
- RCS 1994
- Country
- MAZE United States
- RCS United States
- Employees
- MAZE N/A
- RCS N/A
- Industry
- MAZE
- RCS Investment Managers
- Sector
- MAZE
- RCS Finance
- Exchange
- MAZE NYSE
- RCS Nasdaq
- Market Cap
- MAZE 367.0M
- RCS 296.3M
- IPO Year
- MAZE 2025
- RCS N/A
- Fundamental
- Price
- MAZE $13.07
- RCS $6.76
- Analyst Decision
- MAZE Strong Buy
- RCS
- Analyst Count
- MAZE 3
- RCS 0
- Target Price
- MAZE $25.67
- RCS N/A
- AVG Volume (30 Days)
- MAZE 95.0K
- RCS 141.1K
- Earning Date
- MAZE 05-14-2025
- RCS 01-01-0001
- Dividend Yield
- MAZE N/A
- RCS 10.12%
- EPS Growth
- MAZE N/A
- RCS N/A
- EPS
- MAZE 0.34
- RCS N/A
- Revenue
- MAZE $167,500,000.00
- RCS N/A
- Revenue This Year
- MAZE N/A
- RCS N/A
- Revenue Next Year
- MAZE N/A
- RCS N/A
- P/E Ratio
- MAZE $39.80
- RCS N/A
- Revenue Growth
- MAZE N/A
- RCS N/A
- 52 Week Low
- MAZE $6.71
- RCS $4.51
- 52 Week High
- MAZE $17.00
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- RCS 78.11
- Support Level
- MAZE N/A
- RCS $6.29
- Resistance Level
- MAZE N/A
- RCS $6.77
- Average True Range (ATR)
- MAZE 0.00
- RCS 0.10
- MACD
- MAZE 0.00
- RCS 0.04
- Stochastic Oscillator
- MAZE 0.00
- RCS 95.16
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.